ClinicalTrials.gg
RecruitingNCT07016152Updated Jun 27, 2025

An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults

A Phase 1 interventional study of Glyconjugate Klebsiella pneumoniae bivalent vaccine in Klebsiella Pneumoniae Infection and Vaccine, sponsored by Cho Pharma Inc.. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Cho Pharma Inc. · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

CHO-V08 is currently being developed as a prevention vaccine against nosocomial and community-acquired infection caused by hypervirulent Klebsiella pneumoniae K1 and K2 serotypes. The goal of study (KLEBBI-001) is to evaluate the safety, reactogenicity, and immunogenicity of the preventive vaccine of CHO-V08 in healthy volunteers aged from 18 to 50 years old.

02

Conditions studied

  • Klebsiella Pneumoniae Infection
  • Vaccine

Keywords

  • Klebsiella Pneumoniae Infection
  • Vaccine
03

In context

Lead sponsor

Cho Pharma Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant female, aged 18 to 50 years old (inclusive) for Cohorts 1 and 2 at the Screening visit.
  • (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at the Screening visit.
  • Physically and mentally capable of participating in the study and willing to adhere to study procedures.
  • Able to provide signed .
  • In generally good health by medical history, physical examination, vital signs, and clinical laboratory findings at the Screening visit based on the investigator's judgment.
  • Negative serology test for (HIV) antibody, surface antigen, and antibody at the Screening visit.
  • Female subject with must have a negative result of pregnancy test at the Screening visit.
  • Female subject with childbearing potential must be willing to implement adequate, highly effective measure during the study period.
  • Male subject who agrees to use an adequate method of contraception during the study period.

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition that, in the opinion of the investigator, may interfere with optimal participation in the study or place the subject at increased risk of AEs.
  • Suspected or known (including allergy) to any of the vaccine components.
  • History of hypersensitivity or allergy to any vaccine, especially pneumococcal vaccine.
  • Current or previous, confirmed, or suspected disease caused by Klebsiella pneumoniae.
  • Medical conditions as a to the intramuscular vaccination and blood draws, e.g., coagulation disorder.
  • Any abnormality or permanent body art (e.g., tattoo) that would interfere with the observation of local reactions at the injection site (deltoid region).
  • Acute or chronic, cardiovascular, pulmonary, hepatic or renal diseases and/or insufficiency as determined by physical examination or laboratory tests.
  • Known or suspected impairment of immunological function, e.g., asplenia/splenectomy or history of /immune-mediated diseases or lymphoproliferative disorders.
  • Any screening laboratory abnormalities that are Grade 2 or above or deemed clinically significant in the opinion of the investigator.
  • Subjects with an (ECG) at the Screening visit that demonstrates clinically relevant abnormalities which may affect subject safety or study results in the opinion of the investigator.
  • Positive test for SARS-CoV-2 virus at the Screening visit.
  • Use of any antibiotic therapy within 1 week prior to the first study vaccination.
  • History of any chronic or progressive disease that, according to judgment of the investigator, could interfere with the study outcomes or pose a threat to the subject's health.
  • History of cancer (except localized skin cancer without ) within 5 years prior to the Screening visit.
  • History or presence of heavy smoking (defined as > 10 cigarettes per day; approximately half pack per day) as documented in medical chart or by verbal confirmation at the Screening visit.
  • Documented history of substance or alcohol abuse in the medical chart or by verbal confirmation within 6 months prior to the Screening visit.
  • Received any vaccination (live, inactivated, or bacterial) within 1 month prior to the Screening visit and plans to receive vaccination within 4 weeks after the last study vaccination during the study period. Exception can be made with marketed vaccines against seasonal influenza or COVID-19 outside the 28-day window of the study vaccination.
  • Received major surgery or radiation therapy within 3 months prior to the Screening visit.
  • Onset of influenza-like illness as defined by: fever (temperature ≥ 38℃), dry cough, headache, fatigue, respiratory sputum production, dysgeusia, anosmia, shortness of breath, muscle and joint pain, or sore throat within 1 week prior to the Screening visit.
  • Female subject who is pregnant or lactating at the Screening visit or plans to be pregnant during the study period or lactate from the time of the first vaccination through 60 days after the last vaccination.
  • Received any drug or device or have participated in a clinical study within 3 months prior to the Screening visit.
  • Any confirmed or suspected abnormal immune function, , or immunodeficiency or received any immunosuppressants (including systemic ) or immunomodulators within 3 months prior to the Screening visit.
  • Had blood donation within 2 weeks prior to the Screening visit.
  • Received any blood products or immunoglobulin within 3 months prior to the Screening visit.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    low dose (CHO-V08)

    Biological: Glyconjugate Klebsiella pneumoniae bivalent vaccine

  • Experimental
    high dose (CHO-V08)

    Biological: Glyconjugate Klebsiella pneumoniae bivalent vaccine

Interventions

  • BiologicalGlyconjugate Klebsiella pneumoniae bivalent vaccine

    CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and reactogenicity of the CHO-V08 vaccination.

    Occurrence, severity, and relationship of immediate adverse reactions, solicited, unsolicited adverse events following each vaccination. Occurrence, severity, and relationship of medically-attended AEs (MAAEs), adverse events of special interest (AESIs), new-onset chronic medical conditions (NOCMCs), and serious adverse events (SAEs) through the study completion.

    Time frame: 1 year

Secondary outcomes

  1. To assess the immunogenicity of immunoglobulins M and G (IgM and IgG) following the CHO-V08 vaccination.

    1. Geometric mean titer (GMT) of Kp serotype specific IgM and IgG antibody titers. 2. Seroconversion rate (SCR) in Kp serotype specific IgG antibody titers from baseline. 3. The geometric mean fold rise (GMFR) in Kp serotype specific IgM and IgG antibody titers from baseline.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 11, 2025
StartActual
Jun 26, 2025
Primary completionEst.
Nov 5, 2026
CompletionEst.
Apr 10, 2027
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016152
Lead sponsor
Cho Pharma Inc.
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 26, 2025
Primary completion
Nov 5, 2026 (estimated)
Completion
Apr 10, 2027 (estimated)
Last update
Jun 27, 2025

Study contacts

Tanny Tsao
Contact
tanny.tsao@chopharma.com.tw
886226558059
Ming-Hung Tsai
Contact
haircutter@chopharma.com.tw
886226558059

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion